Tamibarotene

Drug Profile

Tamibarotene

Alternative Names: AM-80; Amnoid; Amnolake; INNO-507; NSC-608000; OMS0728; Retinobenzoic acid; RR-110; SY-1425; Tamibaro; TM-411; TOS-80T; Z-208

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator Shionogi
  • Developer Childrens Hospital Los Angeles; CytRx Corporation; GNI; Nippon Shinyaku; Ohara Pharmaceutical; Syros Pharmaceuticals; TMRC Co. Ltd; Toko Pharmaceutical Industrial; Zeria
  • Class Antineoplastics; Benzoates; Retinoids; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Retinoic acid receptor alpha agonists; Retinoic acid receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I Solid tumours
  • Preclinical Breast cancer; Neutropenia
  • Discontinued Crohn's disease; Hepatocellular carcinoma; Non-small cell lung cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 04 Apr 2017 Pharmacodynamics data from preclinical studies in Acute myeloid leukemia presented at the 108th Annual Meeting of the American Association of Cancer Research (AACR-2017)
  • 20 Mar 2017 Syros pharmaceuticals plans a clinical trial for Acute myeloid leukaemia in Europe during 2017 (Syros pharmaceuticals form 10-K, March 2017)
  • 20 Mar 2017 Syros pharmaceuticals plans a clinical trial for Breast cancer (Syros pharmaceuticals form-10k, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top